Relevance of Benet-Pages BRCA1/BRCA2 VUS reclassification: ACMG/AMP + SVI step (t2) to "Interpret BRCA1/BRCA2 germline variants"
- Use case
- Interpret BRCA1/BRCA2 germline variants
- Assessed by
- Benet-Pages BRCA1/BRCA2 VUS reclassification: ACMG/AMP + SVI step (t2)
- Relevance
- Proxy evidence
- Endpoint
- Fraction of a fixed 121-variant BRCA1/BRCA2 VUS cohort reclassified to likely benign under the ACMG/AMP classification system with current SVI recommendations and new annotation data (t2)
A paired criteria-version reclassification step on a fixed VUS cohort; it measures how many variants move off VUS under a later criteria set, not classification accuracy against independent ground truth or reviewer time.
1 reviewed evaluation
Evidence
Source checking verifies the cited claim or transcription. It does not establish independent reproduction.
Evidence table
Inspect claims, sources and review details
Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.
One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.
15 evidence rows matching the loaded filters
| Property and statement | Original source and location | Review and provenance |
|---|---|---|
Citation locations1 values
| Reclassification of VUS in BRCA1 and BRCA2 using the new BRCA1/BRCA2 ENIGMA track set demonstrates the superiority of ClinGen ENIGMA Expert Panel specifications over the standard ACMG/AMP classification system uc-clinical-20261005-source-benet-pages: Results, Reclassification of variants using the ACMG/AMP classification system with SVI recommendations and new data (ACMG/AMP + SVI) Version: 2025 published article (Genetics in Medicine Open); ENIGMA BRCA1/BRCA2 VCEP specification v1.1.0 applied | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
Constraints1 values
| Reclassification of VUS in BRCA1 and BRCA2 using the new BRCA1/BRCA2 ENIGMA track set demonstrates the superiority of ClinGen ENIGMA Expert Panel specifications over the standard ACMG/AMP classification system uc-clinical-20261005-source-benet-pages: Results, Reclassification of variants using the ACMG/AMP classification system with SVI recommendations and new data (ACMG/AMP + SVI) Version: 2025 published article (Genetics in Medicine Open); ENIGMA BRCA1/BRCA2 VCEP specification v1.1.0 applied | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Endpoint Fraction of a fixed 121-variant BRCA1/BRCA2 VUS cohort reclassified to likely benign under the ACMG/AMP classification system with current SVI recommendations and new annotation data (t2) Context-only references | Reclassification of VUS in BRCA1 and BRCA2 using the new BRCA1/BRCA2 ENIGMA track set demonstrates the superiority of ClinGen ENIGMA Expert Panel specifications over the standard ACMG/AMP classification system uc-clinical-20261005-source-benet-pages: Results, Reclassification of variants using the ACMG/AMP classification system with SVI recommendations and new data (ACMG/AMP + SVI) Version: 2025 published article (Genetics in Medicine Open); ENIGMA BRCA1/BRCA2 VCEP specification v1.1.0 applied | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Claimed field links:assessed_by:uc-clinical-20261005-benet-pages-t2-protocol Context-only references | Reclassification of VUS in BRCA1 and BRCA2 using the new BRCA1/BRCA2 ENIGMA track set demonstrates the superiority of ClinGen ENIGMA Expert Panel specifications over the standard ACMG/AMP classification system uc-clinical-20261005-source-benet-pages: Results, Reclassification of variants using the ACMG/AMP classification system with SVI recommendations and new data (ACMG/AMP + SVI) Version: 2025 published article (Genetics in Medicine Open); ENIGMA BRCA1/BRCA2 VCEP specification v1.1.0 applied | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
Limitations3 values
| Reclassification of VUS in BRCA1 and BRCA2 using the new BRCA1/BRCA2 ENIGMA track set demonstrates the superiority of ClinGen ENIGMA Expert Panel specifications over the standard ACMG/AMP classification system uc-clinical-20261005-source-benet-pages: Results, Reclassification of variants using the ACMG/AMP classification system with SVI recommendations and new data (ACMG/AMP + SVI) Version: 2025 published article (Genetics in Medicine Open); ENIGMA BRCA1/BRCA2 VCEP specification v1.1.0 applied | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
Pinned records6 values
| Reclassification of VUS in BRCA1 and BRCA2 using the new BRCA1/BRCA2 ENIGMA track set demonstrates the superiority of ClinGen ENIGMA Expert Panel specifications over the standard ACMG/AMP classification system uc-clinical-20261005-source-benet-pages: Results, Reclassification of variants using the ACMG/AMP classification system with SVI recommendations and new data (ACMG/AMP + SVI) Version: 2025 published article (Genetics in Medicine Open); ENIGMA BRCA1/BRCA2 VCEP specification v1.1.0 applied | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Rationale A paired criteria-version reclassification step on a fixed VUS cohort; it measures how many variants move off VUS under a later criteria set, not classification accuracy against independent ground truth or reviewer time. Context-only references | Reclassification of VUS in BRCA1 and BRCA2 using the new BRCA1/BRCA2 ENIGMA track set demonstrates the superiority of ClinGen ENIGMA Expert Panel specifications over the standard ACMG/AMP classification system uc-clinical-20261005-source-benet-pages: Results, Reclassification of variants using the ACMG/AMP classification system with SVI recommendations and new data (ACMG/AMP + SVI) Version: 2025 published article (Genetics in Medicine Open); ENIGMA BRCA1/BRCA2 VCEP specification v1.1.0 applied | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Reason Add independently checked primary-source protocol evidence from the additive 2026-10-05 BRCA1/BRCA2 evidence intake (issue #343); scope the endpoint to paired criteria-version reclassification, not accuracy or review time. Context-only references | Reclassification of VUS in BRCA1 and BRCA2 using the new BRCA1/BRCA2 ENIGMA track set demonstrates the superiority of ClinGen ENIGMA Expert Panel specifications over the standard ACMG/AMP classification system uc-clinical-20261005-source-benet-pages: Results, Reclassification of variants using the ACMG/AMP classification system with SVI recommendations and new data (ACMG/AMP + SVI) Version: 2025 published article (Genetics in Medicine Open); ENIGMA BRCA1/BRCA2 VCEP specification v1.1.0 applied | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Relevance proxy Context-only references | Reclassification of VUS in BRCA1 and BRCA2 using the new BRCA1/BRCA2 ENIGMA track set demonstrates the superiority of ClinGen ENIGMA Expert Panel specifications over the standard ACMG/AMP classification system uc-clinical-20261005-source-benet-pages: Results, Reclassification of variants using the ACMG/AMP classification system with SVI recommendations and new data (ACMG/AMP + SVI) Version: 2025 published article (Genetics in Medicine Open); ENIGMA BRCA1/BRCA2 VCEP specification v1.1.0 applied | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Revision 1 Context-only references | Reclassification of VUS in BRCA1 and BRCA2 using the new BRCA1/BRCA2 ENIGMA track set demonstrates the superiority of ClinGen ENIGMA Expert Panel specifications over the standard ACMG/AMP classification system uc-clinical-20261005-source-benet-pages: Results, Reclassification of variants using the ACMG/AMP classification system with SVI recommendations and new data (ACMG/AMP + SVI) Version: 2025 published article (Genetics in Medicine Open); ENIGMA BRCA1/BRCA2 VCEP specification v1.1.0 applied | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
Sources and history
Release 2026-11-21-c8bea25e5abb · Record review: source checked
1 source record and release history
- Reclassification of VUS in BRCA1 and BRCA2 using the new BRCA1/BRCA2 ENIGMA track set demonstrates the superiority of ClinGen ENIGMA Expert Panel specifications over the standard ACMG/AMP classification system · Original source · 2025 published article (Genetics in Medicine Open); ENIGMA BRCA1/BRCA2 VCEP specification v1.1.0 applied
Technical metadata and extraction receipts
Stable ID: use-case-mapping-20261005-343-6620c2b7cd1a
- field
- links:assessed_by:uc-clinical-20261005-benet-pages-t2-protocol
- value
- uc-clinical-20261005-benet-pages-t2-protocol
- relevance
- proxy
- endpoint
- Fraction of a fixed 121-variant BRCA1/BRCA2 VUS cohort reclassified to likely benign under the ACMG/AMP classification system with current SVI recommendations and new annotation data (t2)
- rationale
- A paired criteria-version reclassification step on a fixed VUS cohort; it measures how many variants move off VUS under a later criteria set, not classification accuracy against independent ground truth or reviewer time.
- constraints
- Same 121-variant VUS cohort reclassified across successive criteria-set versions (t1-t2-t3); this mapping covers only the ACMG/AMP + SVI step.
- limitations
- Paired criteria-version reclassification rate, not accuracy against independent ground truth or a reviewer-time comparison.; No independent clinical adjudication of individual calls.; The source's unresolved BRCA1/BRCA2 gene-split sentence (85% n=40 / 83% n=67) is not used in this mapping.
- revision
- 1
- reason
- Add independently checked primary-source protocol evidence from the additive 2026-10-05 BRCA1/BRCA2 evidence intake (issue #343); scope the endpoint to paired criteria-version reclassification, not accuracy or review time.
- citation locators
- source id: uc-clinical-20261005-source-benet-pages; locator: Results, Reclassification of variants using the ACMG/AMP classification system with SVI recommendations and new data (ACMG/AMP + SVI)
- source locator
- uc-clinical-20261005-source-benet-pages: Results, Reclassification of variants using the ACMG/AMP classification system with SVI recommendations and new data (ACMG/AMP + SVI)
- review
- method: automated-source-review; reviewer: claude-sonnet; reviewer note: Claude Sonnet clinical coverage worker (research-evidence intake), root integration review; reviewed at: 2026-10-05T17:39:47.679Z; note: Source-backed literature curation with independent automated transcription and scope checks against the additive 2026-10-05 BRCA1/BRCA2 evidence intake (issue #343). No new model execution, independent experimental replication, qualified human scientific review or clinical validation.
- reviewed evaluations
- uc-clinical-20261005-benet-pages-t2-evaluation
- pins
- record id: uc-clinical-20261005-benet-pages-t2-evaluation; fields: status; links; attributes.origin; attributes.comparison; sha256: b23927a3e734796923ff6e58a45340f9b9ee28e5728b4b3d9a5e7993856e701d; record id: uc-clinical-20261005-benet-pages-t2-protocol; fields: status; name; description; facets; source_ids; links; attributes; sha256: 88d251c476348b5a728fcbd359bf2a5557b8ffd40155dfe7d742724a6502be94; record id: uc-clinical-20261005-benet-pages-t2-reclassified-lb-count; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: e5a6c21dea1f132bf7ef4e091f700b90817b833770ab98511b1a4c1f250d8329; record id: uc-clinical-20261005-benet-pages-t2-reclassified-lb-fraction; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: bbafa5ed5f1310b968ae36392eb04c5f662f6012eac0b360377cb6c12e542b3f; record id: uc-clinical-20261005-source-benet-pages; fields: status; attributes.artifact_sha256; sha256: b5b89b5f7d8e1d2e8b0af3b4224510a0398b9777af95f6e730d88d4e360b7671; record id: use-case-brca1-brca2-germline-interpretation; fields: status; name; description; facets; attributes.question; attributes.decision; attributes.inputs; attributes.output; attributes.exclusions; attributes.setting; attributes.clinical_scope; attributes.intended_users; sha256: 9681ae92e727dde7a801aec8d4884ec28b009d134a52d806a266f7d3b64bd5bd